References
- German J, Sanz MM, Ciocci S, Ye TZ, Ellis NA. Syndrome-causing mutations of the BLM gene in persons in the Bloom’s Syndrome Registry. Hum Mutat 2007; 28:743 - 53; http://dx.doi.org/10.1002/humu.20501; PMID: 17407155
- Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, Ciocci S, et al. The Bloom’s syndrome gene product is homologous to RecQ helicases. Cell 1995; 83:655 - 66; http://dx.doi.org/10.1016/0092-8674(95)90105-1; PMID: 7585968
- Chu WK, Hickson ID. RecQ helicases: multifunctional genome caretakers. Nat Rev Cancer 2009; 9:644 - 54; http://dx.doi.org/10.1038/nrc2682; PMID: 19657341
- Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010; 31:955 - 60; http://dx.doi.org/10.1093/carcin/bgq064; PMID: 20351092
- Nguyen GH, Dexheimer TS, Rosenthal AS, Chu WK, Singh DK, Mosedale G, et al. A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem Biol 2013; 20:55 - 62; http://dx.doi.org/10.1016/j.chembiol.2012.10.016; PMID: 23352139
- Aggarwal M, Sommers JA, Shoemaker RH, Brosh RM Jr.. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci USA 2011; 108:1525 - 30; http://dx.doi.org/10.1073/pnas.1006423108; PMID: 21220316
- Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72:5588 - 99; http://dx.doi.org/10.1158/0008-5472.CAN-12-2753; PMID: 23118055
- Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012; 151:1474 - 87; http://dx.doi.org/10.1016/j.cell.2012.11.054; PMID: 23260137